Structural characterization of a human Fc fragment engineered for lack of effector functions - Wikidata - wikimedia - TriplyDB

Structural characterization of a human Fc fragment engineered for lack of effector functions

Structural characterization of a human Fc fragment engineered for lack of effector functions

http://www.wikidata.org/entity/Q27650876

about

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints Human IgG4: a structural perspective A perspective on the structure and receptor binding properties of immunoglobulin G Fc Structural Determinants of Unique Properties of Human IgG4-Fc Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange.Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies Germinal center B cell depletion diminishes CD4+ follicular T helper cells in autoimmune mice Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody Macrophages are critical effectors of antibody therapies for cancer Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1 Anti-MrkA Monoclonal Antibodies Reveal Distinct Structural and Antigenic Features of MrkA.Self-reactive IgE exacerbates interferon responses associated with autoimmunity.Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.Targeting CD73 in the tumor microenvironment with MEDI9447.Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress.Evaluation of assay interference and interpretation of CXCR4 receptor occupancy results in a preclinical study with MEDI3185, a fully human antibody to CXCR4 CD19 and CD32b differentially regulate human B cell responsiveness.Autoimmune manifestations in aged mice arise from early-life immune dysregulation.Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel anti-transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity.Function and 3D structure of the N-glycans on glycoproteins.Challenges and approaches for the development of safer immunomodulatory biologics.Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.Mouse and human FcR effector functions.Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.Global and Local Conformation of Human IgG Antibody Variants Rationalizes Loss of Thermodynamic Stability.Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy Enhancement of antibody functions through Fc multiplications.Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding.Essential role for CCR6 in certain inflammatory diseases demonstrated using specific antagonist and knockin mice.Spontaneous Secretion of the Citrullination Enzyme PAD2 and Cell Surface Exposure of PAD4 by Neutrophils.The making of bispecific antibodies IgG2m4, an engineered antibody isotype with reduced Fc function.A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.

P2860

Q26738729-ED837A00-BE44-41BA-81EE-E149221F1DF2 Q26779758-22DE278D-5130-470D-897B-4DE09A7FD6FF Q26827579-6FEDE05B-1572-41F8-BD98-8F7707597D0E Q27680566-2CE585DC-D895-4381-A69C-3AF1EE536248 Q28084276-6AF27A6C-D562-4533-8F54-8B784D9E8B58 Q30357905-ABBE8D4A-B9DD-494E-8729-FC38E15D8FBE Q30423024-A65936C4-029B-4D67-86B8-5205A517D0D2 Q33895804-CDAF089E-80BF-412A-AAC6-89CAD78349E4 Q34015403-709D8510-10F2-4DC3-9521-AA7B4D3A4C0D Q35545957-A28D3EFC-BC2E-41C3-8FD8-9F67CE880449 Q36213288-E60949BB-7D31-47C2-A5C0-B642BD1B8F3F Q36213478-7001EEBD-FD2E-4642-B788-055577534C9C Q36255651-A0893B1B-FF9D-44CF-B61B-B3FF2881FE39 Q36479577-E3645178-9933-4868-90CA-0E1EC74D24A1 Q36624176-EFFBDEE7-2B0F-49FA-9FF5-5FB874E469ED Q37224639-6620EEBA-E64A-4DD3-B8C7-2DACF068E320 Q37287000-960ABD8D-46E8-409E-93B2-2C1706780995 Q37318764-49FBD7B2-3D9A-478F-A568-DB9AA9DF5E1A Q37340477-E2399070-71D3-4513-83DC-497D79E0A68E Q37571579-6ED64BC7-9D87-4290-9B4D-A5617AD23748 Q37624299-CDA37390-4FE0-44F8-ADD1-32AF977D3192 Q37713255-E2198360-6FFA-4398-B40D-997497D773AF Q38040103-AC3B400C-9DC2-46CC-8714-7AFB2F3900AA Q38093772-3BB1214E-66B0-4EBE-B975-992D026A1916 Q38208275-06FA8F75-850A-44A1-9AF9-79A031A41872 Q38587550-C8330D85-ED01-4979-87ED-FA6AE95C21F4 Q38615349-84E8BDE1-9A88-455A-BDF4-EBE399233214 Q38615376-B0D8E0C9-403A-49C1-8DE0-4F9E9AFD0ADB Q38748910-E5D6AA2F-D006-4988-BE1F-6660FF78DE30 Q38847426-AF8FCC75-3206-463F-BE70-9E9A6E23DE9C Q38951896-135D1AAD-D225-4872-A861-C7AF3FE7D51E Q38971085-01F4EB61-4CAF-4F7E-9A8B-EB58F6B57C8F Q40365750-D9431A00-1441-4F2D-887D-8B4AA0FC88BA Q40407506-FEF39D13-A396-4B80-9A7D-0405CAF85B96 Q40454744-D7BF0C93-B4CB-4204-A8CA-A8E6A04F6BDF Q41252379-45DC496C-8F9B-4349-9260-A31E6812B9E9 Q42172988-2B3D9A56-6C53-44FC-8D65-5065D90DA8CF Q42323236-02491815-863B-48EB-9B1C-28FF7CC23863 Q42957185-677DAED5-62D9-4013-BED8-BC4288870754 Q45299093-E362F7DE-5B58-46C5-9E71-8E8199EF370C

P2860

Structural characterization of a human Fc fragment engineered for lack of effector functions

http://www.wikidata.org/entity/Q27650876

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Structural characterization of ...... for lack of effector functions

@ast

Structural characterization of ...... for lack of effector functions

@en

Structural characterization of ...... for lack of effector functions

@nl

type

label

Structural characterization of ...... for lack of effector functions

@ast

Structural characterization of ...... for lack of effector functions

@en

Structural characterization of ...... for lack of effector functions

@nl

prefLabel

Structural characterization of ...... for lack of effector functions

@ast

Structural characterization of ...... for lack of effector functions

@en

Structural characterization of ...... for lack of effector functions

@nl

P1433

Q27650876-DD156336-A190-42EE-AB63-127E50C73F04

P1476

Q27650876-310FA0D8-AE9E-4629-B73F-9B8E0781B899

P2093

Q27650876-4AB30EDF-4FCE-46BB-86E6-BCB7080764E0

Q27650876-50D6A7A9-7BE6-4164-8233-E7E1CAFA670A

Q27650876-59218AD3-8312-4C25-9BFB-BCFF6319767B

Q27650876-892DBFF0-88B5-4165-97E9-B4C285B5B959

P2860

Q27650876-05294052-EBE7-4E97-BD94-D11217688C12

Q27650876-12598A84-4067-48F9-B6D4-81B5B2E6F5CA

Q27650876-2DC78FC8-F3CF-4F78-8F89-C895881F6D1A

Q27650876-36E68973-0143-44B2-A79E-A580E3952849

Q27650876-37732FAD-BCD5-46AC-B1EF-49B1A9C12894

Q27650876-40B38256-3B4D-491C-9795-80DD778B83A0

Q27650876-57BE9807-E76F-4584-BDAC-868D2A8C51C4

Q27650876-5ABA593B-CDA7-42A2-9304-5502DAB19AF6

Q27650876-67F75A52-14CC-4234-B0C1-CE77AE04C94F

Q27650876-6A647E2F-D0A2-45A8-B584-6BF3C19F7C9C

P304

Q27650876-86FDEED9-62C8-4E5C-BE2F-8434752855D9

P31

Q27650876-50E71DE3-0C1A-459E-AB9B-2622646497C8

P3181

Q27650876-D2EB0AD4-9E0A-46E3-B787-C74D78C2A1E1

P356

Q27650876-A0DAC064-899A-43AA-9B85-21931E6A4B98

P433

Q27650876-F7304003-F883-4ADE-B5A1-26348EFC6389

P478

Q27650876-71E85EE4-E4B5-4EF4-B9EC-4E1602FE56EA

P50

Q27650876-8D76FAD3-2D3E-4B76-9717-C20CBD4E848A

P577

Q27650876-E8D92A46-8E09-4149-A7F8-6D4787768029

P5875

Q27650876-17EA144E-233F-47DE-8FEC-B0AE7C04B1A4

P698

Q27650876-B1846DE9-3A46-4775-80E3-F49C223E36A5

P921

Q27650876-0B088D3A-476D-4534-BBB4-7B9DA3A26AFB

P932

Q27650876-07562698-3C83-4D10-B1F0-F519763AFB10

P3181

P356

S0907444908007877

P1433

Acta Crystallographica Section D: Biological Crystallography

P1476

Structural characterization of ...... for lack of effector functions

@en

P2093

Changshou Gao

http://www.w3.org/2001/XMLSchema#string

Herren Wu

http://www.w3.org/2001/XMLSchema#string

Lena Shirinian

http://www.w3.org/2001/XMLSchema#string

William F Dall'Acqua

http://www.w3.org/2001/XMLSchema#string

P2860

Improved methods for building protein models in electron density maps and the location of errors in these models

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity

Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1

Structural characterization of a mutated, ADCC-enhanced human Fc fragment

Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution

Likelihood-enhanced fast translation functions

Optimal description of a protein structure in terms of multiple groups undergoing TLS motion

Refinement of macromolecular structures by the maximum-likelihood method

P304

700-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4513066

http://www.w3.org/2001/XMLSchema#string

P356

10.1107/S0907444908007877

http://www.w3.org/2001/XMLSchema#string

P433

Pt 6

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

Vaheh Oganesyan

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5294906

http://www.w3.org/2001/XMLSchema#string

P698

18560159

http://www.w3.org/2001/XMLSchema#string

P921

structural biology

P932

2467532

http://www.w3.org/2001/XMLSchema#string